These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 28716815

  • 1. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer.
    Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS.
    Mol Cancer Ther; 2017 Oct; 16(10):2215-2222. PubMed ID: 28716815
    [Abstract] [Full Text] [Related]

  • 2. Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
    Kim TY, Yen CJ, Al-Batran SE, Ferry D, Gao L, Hsu Y, Cheng R, Orlando M, Ohtsu A.
    Gastric Cancer; 2018 Mar; 21(2):276-284. PubMed ID: 28634748
    [Abstract] [Full Text] [Related]

  • 3. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A, RAINBOW Study Group.
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [Abstract] [Full Text] [Related]

  • 4. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
    Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA.
    Ann Oncol; 2016 Dec; 27(12):2196-2203. PubMed ID: 27765757
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
    Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L.
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
    [Abstract] [Full Text] [Related]

  • 6. Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
    Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB, Gao L, O'Brien LM, Lee P, Zimmermann A, Ferry DR, Melemed AS, Pérol M.
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):77-86. PubMed ID: 29721850
    [Abstract] [Full Text] [Related]

  • 7. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
    Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C.
    J Gastroenterol Hepatol; 2018 Apr; 33(4):814-824. PubMed ID: 28960444
    [Abstract] [Full Text] [Related]

  • 8. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.
    Klempner SJ, Maron SB, Chase L, Lomnicki S, Wainberg ZA, Catenacci DVT.
    Oncologist; 2019 Apr; 24(4):475-482. PubMed ID: 30470690
    [Abstract] [Full Text] [Related]

  • 9. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.
    Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H.
    Ann Oncol; 2016 Apr; 27(4):673-9. PubMed ID: 26747859
    [Abstract] [Full Text] [Related]

  • 10. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
    Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T, Yamaguchi K, Segawa Y, Omuro Y, Tamura T, Doi T, Yukisawa S, Yasui H, Nagashima F, Gotoh M, Esaki T, Emig M, Chandrawansa K, Liepa AM, Wilke H, Ichimiya Y, Ohtsu A.
    Gastric Cancer; 2016 Jul; 19(3):927-38. PubMed ID: 26510663
    [Abstract] [Full Text] [Related]

  • 11. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma.
    Rogers JE, Xiao L, Amlashi FG, Elimova E, Blum Murphy MA, Sanders E, Shanbhag N, Thomas I, Ajani JA.
    Oncology; 2019 Jul; 96(5):252-258. PubMed ID: 30893708
    [Abstract] [Full Text] [Related]

  • 12. Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial.
    Cohn AL, Yoshino T, Heinemann V, Obermannova R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Portnoy DC, Van Cutsem E, Yamazaki K, Clingan PR, Polikoff J, Lonardi S, O'Brien LM, Gao L, Yang L, Ferry D, Nasroulah F, Tabernero J.
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):599-608. PubMed ID: 28744667
    [Abstract] [Full Text] [Related]

  • 13. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.
    Van Cutsem E, Muro K, Cunningham D, Bodoky G, Sobrero A, Cascinu S, Ajani J, Oh SC, Al-Batran SE, Wainberg ZA, Wijayawardana SR, Melemed S, Ferry D, Hozak RR, Ohtsu A, RAINBOW Investigators.
    Eur J Cancer; 2020 Mar; 127():150-157. PubMed ID: 32014812
    [Abstract] [Full Text] [Related]

  • 14. FDA Approval Summary: Ramucirumab for Gastric Cancer.
    Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H, Zhang H, Chen H, He K, Dougherty M, Novak R, Kennett S, Khasar S, Helms W, Keegan P, Pazdur R.
    Clin Cancer Res; 2015 Aug 01; 21(15):3372-6. PubMed ID: 26048277
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Bando H, Shimodaira H, Fujitani K, Takashima A, Yamaguchi K, Nakayama N, Takahashi T, Oki E, Azuma M, Nishina T, Hironaka S, Komatsu Y, Shitara K.
    Eur J Cancer; 2018 Mar 01; 91():86-91. PubMed ID: 29353164
    [Abstract] [Full Text] [Related]

  • 16. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA, RAINFALL Study Group.
    Lancet Oncol; 2019 Mar 01; 20(3):420-435. PubMed ID: 30718072
    [Abstract] [Full Text] [Related]

  • 17. Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer.
    Muro K, Oh SC, Shimada Y, Lee KW, Yen CJ, Chao Y, Cho JY, Cheng R, Carlesi R, Chandrawansa K, Orlando M, Ohtsu A.
    J Gastroenterol Hepatol; 2016 Mar 01; 31(3):581-9. PubMed ID: 26317322
    [Abstract] [Full Text] [Related]

  • 18. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
    Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F.
    BMC Cancer; 2019 Mar 29; 19(1):283. PubMed ID: 30922323
    [Abstract] [Full Text] [Related]

  • 19. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
    Khan U, Shah MA.
    Expert Opin Biol Ther; 2019 Nov 29; 19(11):1135-1141. PubMed ID: 31452409
    [Abstract] [Full Text] [Related]

  • 20. Ramucirumab: A Review in Advanced Gastric Cancer.
    Greig SL, Keating GM.
    BioDrugs; 2015 Oct 29; 29(5):341-51. PubMed ID: 26341713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.